• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluating complement dysregulation in livedoid vasculopathy using a functional assay.

作者信息

Eswaran Harish, Chaturvedi Shruti, Brodsky Robert A, Gerber Gloria F, Pan Xiang-Zuo, Moll Stephan

机构信息

Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.

Divison of Hematology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD.

出版信息

Blood Adv. 2023 Nov 14;7(21):6604-6607. doi: 10.1182/bloodadvances.2022009142.

DOI:10.1182/bloodadvances.2022009142
PMID:37722353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10641098/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b4/10641098/e0fc5f86d04b/BLOODA_ADV-2022-009142-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b4/10641098/e0fc5f86d04b/BLOODA_ADV-2022-009142-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4b4/10641098/e0fc5f86d04b/BLOODA_ADV-2022-009142-gr1.jpg

相似文献

1
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay.使用功能测定法评估类脂质渐进性坏死症中的补体失调。
Blood Adv. 2023 Nov 14;7(21):6604-6607. doi: 10.1182/bloodadvances.2022009142.
2
A novel combination ("CHAP") regimen for management of livedoid vasculopathy in 12 patients.
J Am Acad Dermatol. 2023 Mar;88(3):672-674. doi: 10.1016/j.jaad.2022.06.1188. Epub 2022 Jul 1.
3
Exacerbation of livedoid vasculopathy after coronavirus disease 2019.2019冠状病毒病后类脂质渐进性坏死性血管病加重
Eur J Dermatol. 2022 Jan 1;32(1):129-131. doi: 10.1684/ejd.2022.4200.
4
Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy.关于难治性类脂质渐进性坏死性血管病中疼痛管理及抗肿瘤坏死因子药物疗效的真实世界数据。
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e46-e48. doi: 10.1111/jdv.17613. Epub 2021 Sep 19.
5
Treatment of Livedoid Vasculopathy With Baricitinib.用巴瑞替尼治疗类脂质渐进性坏死性血管病。
JAMA Dermatol. 2022 May 1;158(5):587-589. doi: 10.1001/jamadermatol.2022.0241.
6
Efficacy of adalimumab in the treatment of refractory livedoid vasculopathy: Case report and literature review.阿达木单抗治疗难治性类脂质渐进性坏死性血管病的疗效：病例报告及文献综述
Dermatol Ther. 2022 Sep;35(9):e15666. doi: 10.1111/dth.15666. Epub 2022 Jul 9.
7
Excellent Long-term Clinical Response to Rivaroxaban in Livedoid Vasculopathy: A Retrospective Study.利伐沙班治疗萎缩性血管病的长期临床疗效卓越：一项回顾性研究
Actas Dermosifiliogr. 2023 Feb;114(2):183-185. doi: 10.1016/j.ad.2022.03.022. Epub 2022 Sep 14.
8
The potential role of tumor necrosis factor-α in thrombosis in livedoid vasculopathy.肿瘤坏死因子-α在类脂质渐进性坏死症血栓形成中的潜在作用。
Arch Dermatol Res. 2024 Apr 18;316(5):124. doi: 10.1007/s00403-024-02857-w.
9
Refractory livedoid vasculopathy in a child successfully treated with baricitinib.儿童难治性类脂质渐进性坏死性血管病经巴瑞替尼治疗成功
Dermatol Ther. 2022 Aug;35(8):e15659. doi: 10.1111/dth.15659. Epub 2022 Jul 4.
10
Endothelial dysfunction, thrombophilia, and nailfold capillaroscopic features in livedoid vasculopathy.淤血性血管病变中的血管内皮功能障碍、血栓形成倾向和甲襞毛细血管镜特征。
Microvasc Res. 2023 Nov;150:104591. doi: 10.1016/j.mvr.2023.104591. Epub 2023 Aug 4.

本文引用的文献

1
Livedoid vasculopathy: A review with focus on terminology and pathogenesis.皮肤白细胞碎裂性血管病：术语和发病机制综述。
Vasc Med. 2022 Dec;27(6):593-603. doi: 10.1177/1358863X221130380. Epub 2022 Oct 26.
2
Livedoid vasculopathy - A diagnostic and therapeutic challenge.萎缩性硬化性苔藓样血管病——诊断与治疗的挑战。
Front Med (Lausanne). 2022 Oct 3;9:1012178. doi: 10.3389/fmed.2022.1012178. eCollection 2022.
3
Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.活体样血管病变的直接免疫荧光检查结果：一项 10 年研究及文献回顾。
Clin Exp Dermatol. 2021 Apr;46(3):525-531. doi: 10.1111/ced.14464. Epub 2020 Oct 17.
4
Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.补体活性和补体调节基因的突变与 APS 和 CAPS 中的血栓形成有关。
Blood. 2020 Jan 23;135(4):239-251. doi: 10.1182/blood.2019003863.
5
Complement in the Pathophysiology of the Antiphospholipid Syndrome.补体在抗磷脂综合征发病机制中的作用。
Front Immunol. 2019 Mar 14;10:449. doi: 10.3389/fimmu.2019.00449. eCollection 2019.
6
Livedoid vasculopathy: A review of pathogenesis and principles of management.萎缩性硬化性苔藓样血管病：发病机制与治疗原则综述
Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):478-88. doi: 10.4103/0378-6323.183635.
7
Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.皮肤活检在非典型溶血尿毒综合征诊断中的作用
Am J Dermatopathol. 2015 May;37(5):349-56; quiz 357-9. doi: 10.1097/DAD.0000000000000234.
8
Modified Ham test for atypical hemolytic uremic syndrome.非典型溶血性尿毒症综合征的改良哈姆试验
Blood. 2015 Jun 4;125(23):3637-46. doi: 10.1182/blood-2015-02-629683. Epub 2015 Apr 10.
9
Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome.可溶性C5b-9作为非典型溶血性尿毒症综合征补体激活的生物标志物。
Am J Kidney Dis. 2015 Jun;65(6):968-9. doi: 10.1053/j.ajkd.2015.02.326. Epub 2015 Mar 25.
10
Is there an association between complement activation and antiphospholipid antibody-related thrombosis?补体激活与抗磷脂抗体相关血栓形成之间是否存在关联？
Thromb Haemost. 2010 Dec;104(6):1279-81. doi: 10.1160/TH10-06-0410. Epub 2010 Sep 13.